Skip to content

Discovery of biomarkers for immune-mediated liver disease.

Discovery of non-invasive biomarkers for immune-mediated liver diseases; AIH, DILI, NAFL and NASH.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON24228
Enrollment
Unknown
Registered
2017-03-30
Start date
2017-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune hepatitis, drug-induced liver injury, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Interventions

One extra needle passage during a liver biopsy that is part of usual care.

Sponsors

Investigator initiated study, funded by the Vrije Universiteit, University Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Indication for a biopsy for the diagnosis or monitoring of; AIH, DILI, NAFL or NASH Eligible for liver biopsy ¡Ý 18 years old Provide informed consent

Exclusion criteria

Exclusion criteria: Contraindication for liver biopsy, determined by the clinician. Current infectious disease. Clinically relevant cardiovascular, pulmonary, or renal disease. Medications with possible immune-modulating effects (e.g., steroids). (a history of) alcohol or drug abuse

Design outcomes

Primary

MeasureTime frame
Immunophenotype of intrahepatic leucocytes.

Secondary

MeasureTime frame
Histology outcome

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)